PARSIPPANY, N.J.– Professional golfer Azahara (Aza) Muñoz will return to the LPGA Tour this fall as a new mom and as the new spokesperson for Tirosint®-SOL (levothyroxine sodium) solution. Muñoz has partnered with IBSA Pharma Inc. to promote Tirosint-SOL, a unique liquid hypothyroidism treatment. Muñoz suffers from Hashimoto’s Thyroiditis, an autoimmune condition that attacks a person’s thyroid gland and produces symptoms of hypothyroidism, which include lethargy, weight gain, dry skin, and a heightened sensitivity to the cold.
“Before Tirosint-SOL, I tried taking conventional thyroid hormone tablets, but I never felt like myself. My body ached, and practicing golf was so tough because I was always tired,” said Muñoz. “Since I started taking Tirosint-SOL, it’s been a game-changer. I’m excited to wake up every morning knowing I actually have the energy to practice my golf game and to play with my newborn son. I’m back in full swing – both on and off the course. I’m ready for my return to competition.”
As part of the partnership, Muñoz will appear as a spokesperson at in-person events and on social media to promote the brand while wearing the Tirosint-SOL logo on the sleeve of her golf attire.
Prior to Muñoz’s diagnosis in 2016, she thought that her symptoms were from the stress of playing professional golf. After months of continuing symptoms, she went to the doctor and was diagnosed with Hashimoto’s Thyroiditis. She tried to treat her condition using conventional thyroid medicine, but she still struggled with the symptoms of hypothyroidism. While on maternity leave in 2021, Muñoz was prescribed Tirosint-SOL to treat her condition and has taken the medication daily ever since.
Tirosint-SOL is the first liquid formulation approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypothyroidism, a condition in which a person cannot make enough thyroid hormone to meet their body’s needs. Tirosint-SOL has been clinically proven to effectively treat the full spectrum of hypothyroid patients, from patients with general hypothyroidism to those who have concomitant conditions or who are taking other medications that can complicate therapy.
With only three ingredients – levothyroxine, glycerol, and water – Tirosint-SOL does not contain other inactive ingredients or preservatives that are commonly found in traditional levothyroxine tablet therapies. These excipients can interfere with the tolerability or absorption of thyroid medication.1
Tirosint-SOL has 15 dosing strengths, the widest range of any therapy for hypothyroidism available in the U.S. It is the only FDA-approved levothyroxine formulation that comes in unique monodose packaging for precision and convenience.
“As Aza stated, Tirosint-SOL was a game changer for her, and we think her partnership is a game changer for IBSA Pharma,” said Michael Scully, head of commercial operations, IBSA Pharma Inc. “To hear firsthand from a LPGA Tour player about how the product was able to effectively treat her hypothyroidism and get her back into the game is just tremendous. Hopefully, other patients can benefit from hearing Aza’s experience and seek a treatment option like Tirosint SOL. We wish Aza the best of luck and health as she returns to the Tour!”
